Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
Mation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10589866	
INFORMATION BIOCH COURT	Filing Date		2006-09-19	
INFORMATION DISCLOSURE	First Named Inventor BERG		COVIER	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		1645	
( Not for Submission under 07 of K 1.00)	Examiner Name	DEVI		
	Attorney Docket Number	er	27637U	

U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	of cited Document		s,Columns,Lines where ant Passages or Relevant es Appear		
	1									
If you wis	h to ad	d additional U.S. Pate	 ent citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT.	APPLIC	CATION PUBI	LICATIONS		Remove	
Examiner Initial*	I Cito No I			I	Publication Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1				No. of the last of					
If you wis	h to ad	d additional U.S. Pub	lished Ap	•		•		d button		
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*		Foreign Document Number³	Country Code <sup>2</sup>	, ,	Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	e or V F	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	4				STATE OF THE PARTY			***************************************		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T5	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10589866		
Filing Date		2006-09-19		
First Named Inventor BERC		COVIER		
Art Unit		1645		
Examiner Name DEVI				
Attorney Docket Number		27637U		

/S.D./	1	NIGOU, et al., "Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor", The Journal of Immunology, vol. 166, pgs. 7477-7485, (2001).	
/S.D./	2	NIGOU, et al., "Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response", Microbes and Infection, vol. 4, pgs. 945-953, (2002).	
/S.D./	3	OLSON, et al., "Design and Synthesis of a Protein β-Turn Mimetic", J. Am. Chem. Soc., vol. 112, pgs. 323-333, (1990).	
/S.D./	4	PINCUS, et al., "Peptides That Mimic the Group B Streptococcal Type III Capsular Polysaccharide Antigen", The Journal of Immunology, vol. 160, pgs. 293-298, (1998).	
/S.D./	5	PRINZIS, et al., "Structure and anitgenicity of lipoarabinomannan from Mycobacterium bovis BCG", Journal of General Microbiology, vol. 139, pgs. 2649-2658, (1993).	
/S.D./	6	QUESNIAUX, et al., "Toll-Like Receptor 2 (TLR2)-Dependent-Positive and TLR2-Independent-Negative Regulation of Proinflammatory Cytokines by Mycobacterial Lipomannans", The Journal of Immunology, vol. 172, pgs. 4425-4434, (2004).	
/S.D./	7	SCHLESINGER, et al., "Binding of the Terminal Mannosyl Units of Lipoarabinomannan from a Virulent Strain of Mycobacterium Tuberculosis to Human Macrophages", Journal of Immunology, vol. 152, pgs. 4070-4079, (1994).	
/S.D./	8	SETHI, et al., "Contraction-Mediated Pinocytosis of RGD-Peptide By Dermal Fibroblasts: Inhibition of Matrix Attachment Blocks Contraction and Disrupts Microfilament Organisation", Cell Motility and Cytoskeleton, vol. 52, pgs. 231-241, (2002).	
/S.D./	9	SHIRAKAWA, et al., "The Inverse Association Between Tuberculin Responses and Atopic Disorder", Science, vol. 275, pgs. 77-79, (1997).	
/S.D./	10	SHIRTCLIFFE, et al., "An inverse correlation between estimated tuberculosis notification rates and asthma symptoms", Respirology, vol. 7, pgs. 153-155, (2002).	
/S.D./	11	SINGH, et al., "Advances in Vaccine Adjuvants for Infectious Diseases", Current HIV Research, vol. 1, pgs. 309-320, (2003).	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10589866		
Filing Date		2006-09-19		
First Named Inventor BERC		COVIER		
Art Unit		1645		
Examiner Name DEVI				
Attorney Docket Number		27637U		

/S.D./	12	SMITH, et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage", Methods in Enzymology, vol. 217, pgs. 228-257, (1993).	
/S.D./	13	STERN, et al., "Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library", FASEB J., vol. 11, pgs. 147-153, (1997).	
/S.D./	14	TEMKIN, et al., "Tumor necrosis factors in a murine model of allergic peritonitis: effects on eosinophil accumulation and inflammatory mediators' release", Cytokine, vol. 24, pgs. 74-80, (2003).	
/S.D./	15	TIBBETTS, et al., "Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function", Peptides, vol. 21, pgs. 1161-1167, (2000).	
/S.D./	16	VALADON, et al., "Enhancement of ELISAs for screening peptides in epitope phage display libraries", Journal of Immunological Methods, vol. 197, pgs. 171-179, (1996).	
/S.D./	17	VON MUTIUS, et al., "International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema", Thorax, vol. 55, pgs. 449-453, (2000).	
/S.D./	18	VYAS, et al., "Structural basis of peptide-carbohydrate mimicry in an antibody-combining site", PNAS, vol. 100, no. 25, pgs. 15023-15028, (2003).	
/S.D./	19	WANG, et al., "Epitope Identification and Discovery Using Phage Display Libraries: Applications in Vaccine Development and Diagnostics", Current Drug Targets, vol. 5, pgs. 1-15, (2004).	
/S.D./	20	WU, et al., "The Pharmacological Actions of Nicotine on the Gastrointestinal Tract", Journal of Pharmacological Sciences, vol. 94, pgs. 348-358, (2004).	
/S.D./	21	YOSHIMURA, et al., "Role of NFkB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", Eur. J. Immunol., vol. 31, pgs. 1883-1893, (2001).	
/S.D./	22	ZABROCKI, et al., "Conformational Mimicry. 1. 1,5-Disubstituted Tetrazole Ring as a Surrogate for the Cis Amide Bond", J. Am. Chem. Soc., vol. 110, pgs. 5875-5880, (1988).	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10589866		
Filing Date		2006-09-19		
First Named Inventor BERC		COVIER		
Art Unit		1645		
Examiner Name DEVI				
Attorney Docket Number		27637U		

/S.D./	23	ZECHEL, et al., "Synthetic glucagon antagonists and partial agonists", Int. J. Peptide Protein Res., vol. 38, pgs. 131-138, (1991).						
/S.D./	24	ZUANY-AMORIM, et al., "Suppression of airway eosinophilia by killed mycobacerium vaccae-induced allergen-specific regulatory T-cells", Nature Medicine, vol. 8, no. 6, pgs. 625-629, (2002).						
/S.D./	25	MIYAKK, et al., "1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Angiotensin: Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives", J. Takeda Res. Labs., vol. 43, pgs. 53-76, (1984).						
/S.D./	DELUCA, et al., "Parenteral Drug-Delivery Systems", Pharmaceutics and Pharmacy Practice, ch. 8, pgs. 238-250, J.B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., (1982).							
/S.D./	27	TRISSEL, "Intravenous Infusion Solutions", ASHP Handbook on Injectable Drugs, 4th ed., pgs. 622-630, (1986).						
/S.D./	ENSHELL-SEIJFFERS, et al., "Phage Display Selection and Analysis of Ab-Binding Epitopes", Current Protocols in Immunology, vol. 2, pgs. 9.8.1-9.8.27, (2002).							
If you wis	h to ac	d additional non	-patent literatu	re document cit	tation information p	please click the Add b	outton Add	
				EXAMINE	R SIGNATURE			
Examiner	Examiner Signature /S. Devi/ Date Considered 12/07/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								